Welcome to our dedicated page for Antibe Therapeut news (Ticker: ATBPF), a resource for investors and traders seeking the latest updates and insights on Antibe Therapeut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Antibe Therapeut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Antibe Therapeut's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in the Precision in Clinical Trials Summit in Boston on May 1-2, 2023. Chief Medical Officer Dr. Joseph Stauffer will present Antibe’s clinical program for otenaproxesul, a drug designed to provide safer pain relief alternatives to opioids and NSAIDs, particularly addressing gastrointestinal side effects. Antibe's pipeline includes ATB-352, targeting specialized pain indications and aims to develop new therapies for inflammatory bowel disease. This summit offers a platform for clinical trial professionals to discuss innovations in the field.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) has announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25-26, 2023. The Company, focused on developing safer therapies for inflammation using its hydrogen sulfide platform, will present on April 26, 2023, at 1:30 pm ET at the Metro Toronto Convention Centre.
Chief Operating Officer Scott Curtis and Chief Medical Officer Dr. Joseph Stauffer will lead the presentation. A webcast link is available on the Company’s website and will remain accessible for 90 days. The conference aims to connect investors with developments from various companies in the Canadian healthcare sector.
Antibe's pipeline includes drugs targeting GI issues from NSAIDs and alternatives for opioids. Learn more at antibethera.com.